Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Aurinia Pharmaceuticals Inc AUPH

Healthcare Biotechnology
Aurinia Pharmaceuticals Inc. is a Canada-based fully integrated biopharmaceutical company. The Company is focused on delivering therapies to treat targeted patient populations with a high unmet medical need that are impacted by autoimmune, kidney and rare diseases. The Company has developed LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis... see more

Recent & Breaking News (NDAQ:AUPH)

Aurinia Resolves Temporary Non-Compliance with Nasdaq’s Audit Committee Composition Rule

Business Wire July 12, 2017

Aurinia Announces Results of Annual General Meeting

Business Wire June 22, 2017

Aurinia to Host Annual General Meeting of Shareholders and Webcast on June 21 in Vancouver, BC

Business Wire June 21, 2017

Ongoing Aurinia Pharmaceuticals Study Results Boost Shares Higher

Benzinga.com  June 16, 2017

Voclosporin Remission Data from the Phase IIb AURA-LV Study Highlighted at EULAR 2017

Business Wire June 16, 2017

Technical Snapshots for These Biotech Stocks -- Gilead Sciences, Aurinia Pharma, Esperion Therapeutics, and Alexion Pharma

PR Newswire June 8, 2017

Aurinia Presents Additional Data from Phase Iib Aura-Lv Study, Demonstrating Stable Renal Function and Blood Pressure without Electrolyte Complications Through 48 Weeks

Business Wire June 5, 2017

Aurinia to Participate in Late Breaking Oral Presentations at Two Upcoming Scientific Conferences

Business Wire May 30, 2017

Aurinia Doses First Patient in AURORA Phase 3 Clinical Trial of Voclosporin in Lupus Nephritis

Business Wire May 17, 2017

Aurinia Reports First Quarter 2017 Financial Results, Announces Initiation of Phase III Aurora Clinical Trial, and Provides Operational Highlights

Business Wire May 15, 2017

The Growth of the Global Pharmaceuticals Market

PR Newswire May 9, 2017

Pharma Industry Veteran Dr. George Milne Joins Aurinia’s Board of Directors

Business Wire May 9, 2017

Aurinia to Present at Bloom Burton & Co. Healthcare Conference

Business Wire April 26, 2017

Aurinia Releases Additional 48-Week Data from the AURA-LV Study During Late-Breaking Session at the National Kidney Foundation 2017 Spring Clinical Meetings

Business Wire April 20, 2017

Aurinia Completes Licensing Deal with Merck Animal Health for Its Nanomicellar Formulation of Voclosporin for the Treatment of Canine Dry Eye Syndrome

Business Wire April 17, 2017

Aurinia Pharma Shares Could Be A 2-Bagger From Here

Benzinga.com  April 11, 2017

Aurinia to Host Investor Event and Webcast on April 20th in Orlando, FL

Business Wire April 10, 2017

12 Biggest Mid-Day Gainers For Friday

Benzinga.com  April 7, 2017

18 Stocks Moving In Friday's Pre-Market Session

Benzinga.com  April 7, 2017

Aurinia Announces Development Plans for Voclosporin in Europe and Japan

Business Wire April 6, 2017